---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-23-003238"
form_type: "8-K"
ticker: "VNRX"
cik: "0000093314"
company_name: "VOLITIONRX LTD"
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T07:43:46.329331+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# VolitionRx Q1 sales jump 381% to $124k; cash $10M; expects $13M milestones

## Summary
- Nu.Q Vet Cancer Test sales rose 381% YoY to $124,000 in Q1 2023.
- Cash and equivalents $10.0M at March 31, 2023 vs $10.9M at year-end 2022.
- Received ~$8M net from Feb public offering; expects $13M in Heska milestone payments and additional non-dilutive Belgian funding.
- Launched Nu.Q Vet Cancer Test through IDEXX and Heska; planning more country launches in 2023.
- Advancing Nu.Q NETs test for sepsis with multi-site U.S. studies and FDA Breakthrough Device application.

## SEC filing metadata
- accession: 0001477932-23-003238
- form_type: 8-K
- ticker: VNRX
- cik: 0000093314
- company_name: VOLITIONRX LTD
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/93314/000147793223003238/0001477932-23-003238-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/93314/000147793223003238/vnrx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-23-003238
- JSON: https://secwatch.observer/filing/0001477932-23-003238.json
- Plain text: https://secwatch.observer/filing/0001477932-23-003238.txt

## Key facts
- Earnings Releases
  VOLITIONRX LTD reported financial results for the first quarter ended March 31, 2023.
  - Period: the first quarter ended March 31, 2023
  - Result: reported results
  source text: VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced financial results and a business update for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/93314/000147793223003238/0001477932-23-003238-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.